Literature DB >> 17846346

Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension.

Begoña López1, José M Castellano, Arantxa González, Joaquín Barba, Javier Díez.   

Abstract

Inappropriate left ventricular mass is present when the value of left ventricular mass exceeds individual needs to compensate hemodynamic load imposed by increased blood pressure. The goal of this study was to investigate whether plasma concentration of cardiotrophin-1, a cytokine that induces exaggerated hypertrophy in cardiomyocytes with hypertensive phenotype, is related to inappropriate left ventricular mass in patients with essential hypertension. The study was performed in 118 patients with never-treated hypertension and without prevalent cardiac disease. The left ventricular mass prediction from stroke work (systolic blood pressurexDoppler stroke volume), sex, and height (in meters(2.7)) was derived. An observed left ventricular mass/predicted left ventricular mass value >128% defined inappropriate left ventricular mass. Plasma cardiotrophin-1 was measured by an enzyme-linked immunosorbent assay. The studies were repeated in a group of 45 patients after 1 year of antihypertensive treatment. At baseline 67 and 51 patients presented with appropriate and inappropriate left ventricular mass, respectively. Plasma cardiotrophin-1 was higher (P<0.001) in patients with inappropriate mass than in patients with appropriate mass and normotensive controls. A direct correlation was found between cardiotrophin-1 and observed left ventricular mass/predicted left ventricular mass ratio (r=0.330, P<0.001) in all hypertensive patients. After treatment, plasma cardiotrophin-1 decreased and increased in patients in which inappropriate left ventricular mass regressed and persisted, respectively, despite a similar reduction of blood pressure in the 2 subgroups of patients. Albeit descriptive in nature, these results suggest the hypothesis that an excess of cardiotrophin-1 may contribute to inappropriate left ventricular growth in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846346     DOI: 10.1161/HYPERTENSIONAHA.107.098111

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

Review 1.  Circulating biomarkers in the early detection of hypertensive heart disease: usefulness in the developing world.

Authors:  Dike Ojji; Elena Libhaber; Kim Lamont; Friedrich Thienemann; Karen Sliwa
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

Review 2.  Cardiotrophin-1 in hypertensive heart disease.

Authors:  Arantxa González; Begoña López; Susana Ravassa; Javier Beaumont; Amaia Zudaire; Idoia Gallego; Cristina Brugnolaro; Javier Díez
Journal:  Endocrine       Date:  2012-03-15       Impact factor: 3.633

Review 3.  STAT3 and cardiac remodeling.

Authors:  Arash Haghikia; Britta Stapel; Melanie Hoch; Denise Hilfiker-Kleiner
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

4.  Skin autofluorescence is associated with inappropriate left ventricular mass and diastolic dysfunction in subjects at risk for cardiovascular disease.

Authors:  Chun-Cheng Wang; Yao-Chang Wang; Guei-Jane Wang; Ming-Yi Shen; Yen-Lin Chang; Show-Yih Liou; Hung-Chih Chen; An-Sheng Lee; Kuan-Cheng Chang; Wei-Yu Chen; Chiz-Tzung Chang
Journal:  Cardiovasc Diabetol       Date:  2017-01-25       Impact factor: 9.951

Review 5.  Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis.

Authors:  Kangxing Song; Shuxia Wang; Bihui Huang; Amelia Luciano; Roshni Srivastava; Arya Mani
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-07-23       Impact factor: 3.738

Review 6.  Integrating the myocardial matrix into heart failure recognition and management.

Authors:  Francis G Spinale; Michael R Zile
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

7.  Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.

Authors:  Jacqueline N Minas; Max A Thorwald; Debra Conte; Jose-Pablo Vázquez-Medina; Akira Nishiyama; Rudy M Ortiz
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-11       Impact factor: 2.557

8.  Serum cardiotrophin-1 and IL-6 levels in patients with obstructive sleep apnea syndrome.

Authors:  Ozlem Kar Kurt; Mehmet Tosun; Fahrettin Talay
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

9.  Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure.

Authors:  Atac Celik; Semsettin Sahin; Fatih Koc; Metin Karayakali; Mehmet Sahin; Ismail Benli; Hasan Kadi; Turgay Burucu; Koksal Ceyhan; Unal Erkorkmaz
Journal:  Med Sci Monit       Date:  2012-01

10.  Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk.

Authors:  Luis Gamella-Pozuelo; Isabel Fuentes-Calvo; Manuel A Gómez-Marcos; José I Recio-Rodriguez; Cristina Agudo-Conde; José L Fernández-Martín; Jorge B Cannata-Andía; José M López-Novoa; Luis García-Ortiz; Carlos Martínez-Salgado
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.